In vivo comparison of a polymer‐free Biolimus A9‐eluting stent with a biodegradable polymer‐based Biolimus A9 eluting stent and a bare metal stent in balloon denuded and radiated hypercholesterolemic rabbit iliac arteries

Objectives: To evaluate the effect of a polymer‐free Biolimus A9‐eluting stent [BioFreedom™ (BF)], compared with that of a biodegradable polymer‐based Biolimus A9‐eluting stent [BioMatrix Flex™ (BMF)] and a bare metal stent (BMS) in balloon denuded and radiated hypercholesterolemic rabbit iliac arteries. Methods: Rabbits were fed with 1% cholesterol diet (n = 14) for 14 days, both iliac arteries were balloon denuded and radiated, and then rabbits were switched to 0.15% cholesterol diet. After 4 weeks, BF (n = 8), BMF (n = 8), and BMS (n = 8) were deployed in denuded and radiated areas. Four weeks later animals were euthanized, arterial segments were processed for morphometry. Results: The neointimal area in vessels implanted with BF stents was significantly less than that seen in vessels implanted with BMS (0.90 mm2 ± 0.14 vs. 1.29 mm2 ± 0.23, P <0.01). Percent fibrin and fibrin score were higher with BMF stents compared to BMS (P <0.03 and <0.04) and giant cell number was significantly higher with both BMF and BF stents (P < 0.01 for both). Percent endothelialization was significantly higher and % uncovered struts were lower with BMS compared to either BMF or BF stents (P < 0.05 for both). Conclusion: This study demonstrates that compared to BMS, BF stents significantly decreased neointimal hyperplasia. © 2011 Wiley Periodicals, Inc.

[1]  A. Küttner,et al.  Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. , 1997, Circulation.

[2]  M. Leon,et al.  In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. , 1998, Journal of the American College of Cardiology.

[3]  J. Pouysségur,et al.  p70 S6 Kinase-mediated Protein Synthesis Is a Critical Step for Vascular Endothelial Cell Proliferation* , 1999, The Journal of Biological Chemistry.

[4]  Benno J. Rensing,et al.  Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up , 2001, Circulation.

[5]  P. Tsao,et al.  Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model , 2001, Circulation.

[6]  C. Di Mario,et al.  First Clinical Experience With a Paclitaxel Derivate–Eluting Polymer Stent System Implantation for In-Stent Restenosis: Immediate and Long-Term Clinical and Angiographic Outcome , 2002, Circulation.

[7]  R. Virmani,et al.  Radiation-induced atherosclerotic plaque progression in a hypercholesterolemic rabbit: a prospective vulnerable plaque model? , 2003, Cardiovascular radiation medicine.

[8]  Patrick W Serruys,et al.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.

[9]  Giuseppe Musumeci,et al.  Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.

[10]  R. Pakala,et al.  Effect of Antioxidants on Atherosclerotic Plaque Formation in Balloon-Denuded and Irradiated Hypercholesterolemic Rabbits , 2005, Journal of cardiovascular pharmacology.

[11]  R. Falotico,et al.  Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. , 2005, European journal of pharmacology.

[12]  A. Kastrati,et al.  Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. , 2005, Annals of internal medicine.

[13]  Matthew H Samore,et al.  Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. , 2006, Journal of the American College of Cardiology.

[14]  Patrick Hunziker,et al.  Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.

[15]  R. Virmani,et al.  Peroxisome Proliferator-Activated Receptor γ Ligand Pioglitazone Alters Neointimal Composition in a Balloon-Denuded and Radiated Hypercholesterolemic Rabbit , 2006, Journal of cardiovascular pharmacology.

[16]  L. Buellesfeld,et al.  BioMatrix® Biolimus A9®-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease , 2006, Expert review of medical devices.

[17]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[18]  Jörg Hausleiter,et al.  Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen Loss , 2006, Circulation.

[19]  Michael Joner,et al.  Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[20]  P. Serruys,et al.  A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[21]  S. Pocock,et al.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.

[22]  Ralph D'Agostino,et al.  Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.

[23]  Marco Valgimigli,et al.  Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[24]  Michael Joner,et al.  Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications , 2007, Circulation.

[25]  A. Wieczorek,et al.  Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. , 2008, European heart journal.

[26]  F. Eberli,et al.  Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2008, The Lancet.

[27]  R. Virmani,et al.  Effect of clopidogrel on neointimal formation and inflammation in balloon-denuded and radiated hypercholesterolemic rabbit iliac arteries , 2008 .

[28]  R. Virmani,et al.  Effect of clopidogrel on neointimal formation and inflammation in balloon-denuded and radiated hypercholesterolemic rabbit iliac arteries. , 2008, Journal of interventional cardiology.

[29]  R. Virmani,et al.  Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents. , 2008, JACC. Cardiovascular interventions.

[30]  Aloke V. Finn,et al.  Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study , 2008, Circulation.

[31]  M. Joner,et al.  Polymer coatings and delayed arterial healing following drug-eluting stent implantation. , 2009, Minerva cardioangiologica.

[32]  A. Kastrati,et al.  A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. , 2008, European heart journal.

[33]  Jörg Hausleiter,et al.  The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. , 2009, Biomaterials.